PDCD1 and neoplasm: Ren et al. [86] also found that CAR T cells that use CRISPR to knock down the PD-1 encoding gene, PDCD1, exhibited potent anti-tumor activity both in vitro and in animal models, suggesting that such CAR T cells lacking this checkpoint receptor might be beneficial.